Physician profile
Binoy Ouseph
NPI 1497797880
$6,996.45
in general payments reported to CMS, 2019-2025
27 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $320 · 2021: $629 · 2022: $234 · 2023: $1,183 · 2024: $1,353 · 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731 · Travel and Lodging: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.75 |
| Travel and Lodging | $1,876.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,969.02 | 2021-2025 | Spyglass, Axios, Acquire |
| Abbvie INC. | $1,667.10 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $581.16 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $413.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $378.90 | 2025 | Disposable Biopsy Forceps, Olympus, Endoclot Sis |
| Phathom Pharmaceuticals, INC. | $284.82 | 2024 | Voquezna |
| Janssen Biotech, INC. | $263.12 | 2021-2025 | Tremfya, Stelara |
| Pfizer INC. | $206.86 | 2019-2025 | |
| Erbe USA INC | $200.00 | 2023 | Erbe Vio |
| Regeneron Healthcare Solutions, INC. | $164.42 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $156.08 | 2020-2024 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $120.45 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $111.30 | 2019-2020 | |
| Braintree Laboratories, INC. | $70.60 | 2021-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.79 | 2020-2024 | Xifaxan |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $64.61 | 2023-2024 | Rebyota |
| Genzyme Corporation | $53.91 | 2023-2025 | |
| Lilly USA, LLC | $37.57 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $36.96 | 2021-2022 | |
| Cook Medical LLC | $32.57 | 2025 | Echotip Insight, Hemospray |
| Celgene Corporation | $29.79 | 2022-2023 | Zeposia |
| Echosens North America, INC. | $20.18 | 2025 | Fibroscan |
| Ipsen Biopharmaceuticals, INC | $16.81 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $13.99 | 2021 | |
| Celltrion USA INC. | $13.66 | 2024 | Vegzelma |
| Alfasigma USA, INC. | $12.94 | 2020 | |
| Vivus LLC | $10.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Binoy Ouseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.